Therapeutic messenger RNA (mRNA) is frequently redesigned through synonymous coding substitutions intended to improve stability and expression without changing the encoded amino-acid sequence. Yet RNA persistence, ribosomal translation, nascent-chain folding, and biologically active protein accumulation are distinct outcomes; optimization of one cannot guarantee improvement of the others. This mechanism-based theoretical article integrates experimental and computational evidence on codon choice, RNA structure, decoding state, translational quality control, and cotranslational folding. We argue that sequence designs may change rank when evaluated by functional protein output instead of RNA half-life or bulk expression, provided that folding, processing, and activity are sensitive to the translation history of otherwise identical polypeptides. The account separates established sequence-dependent mechanisms from the proposed coupling among intermediate processes. It identifies contextual dependence on cell state, nucleoside chemistry, delivery, and measurement timescale, while treating direct therapeutic validation as outstanding. A falsifiable, matched-construct approach is proposed for distinguishing RNA abundance, productive translation, maturation efficiency, and active-product formation. Synonymous sequence selection should consequently be judged against the function required of the encoded therapeutic product, with gains in stability or quantity interpreted as conditional evidence.
IJPRAS
